35 results on '"Leukemia--Treatment"'
Search Results
2. Acute mast cell leukaemia case study
- Author
-
Jeong Min, Hyeon
- Published
- 2023
3. Chronic myeloid leukaemia
- Author
-
Li, Eric Wenlong and Yeung, David
- Published
- 2020
4. Gerri's journey: A walk for mum
- Author
-
Stevens, Leigh
- Published
- 2022
5. Cold autoimmune haemolytic anaemia as the presenting feature in a patient with angioimmunoblastic t-cell lymphoma - an illustrative case
- Author
-
Gates, Shirley May and Lombard, Elizabeth
- Published
- 2020
6. Frontiers in Leukemia Pharmacotherapy
- Author
-
Lunawati Bennett and Lunawati Bennett
- Subjects
- Leukemia--Treatment, Leukemia--Chemotherapy, Chemotherapy
- Abstract
Frontiers in Leukemia Pharmacotherapy provides a comprehensive overview of the various leukemic disorders found in both children and adults, with an emphasis on current and novel treatment approaches for the healthcare practitioner. By focusing on the unique therapeutic challenges of leukemia, this book aims to meet the diverse needs of physicians, pharmacists, nurses, and other healthcare professionals with an interest in serving patients with leukemia. This comprehensive book is divided into nineteen chapters. Content includes information on specific leukemic disease states in both children and adults. Written by researchers and clinical practitioners, chapters cover a wide array of leukemic topics. Topics include understanding the molecular and genetic basis of acute and chronic leukemia, pharmacology of anti-leukemic agents including traditional chemotherapies, targeted immunotherapy, and tyrosine kinase inhibitors. The epidemiology, etiology, pathogenesis, disease classification, clinical presentation, pathologic features, diagnosis, prognosis, and treatment guidelines for myelodysplastic syndrome, promyelocytic leukemia, pediatric and adult acute and chronic leukemia are other topics covered in more detail. Other topics include: Redox homeostasis occurring in leukemia and the role of antioxidants, supportive care for the leukemic patient experiencing complications from chemotherapy, palliative care for termination of those with leukemia, pharmacometrics using computational modeling to support drug development in leukemia, and future agents that are in clinical trials in our fight against leukemia. Reputable books, journals, monograms, clinical trials, and other resources were used to provide up-to-date medical information useful to assist healthcare professionals in the management of leukemia. Frontiers in Leukemia Pharmacotherapy is an excellent resource for curious healthcare professionals involved in the care of leukemic disorders.
- Published
- 2019
7. Acute Leukemia : An Illustrated Guide to Diagnosis and Treatment
- Author
-
Ashkan Emadi, MD, PhD, Judith E. Karp, MD, Ashkan Emadi, MD, PhD, and Judith E. Karp, MD
- Subjects
- Acute diseases, Leukemia--Treatment, Leukemia--Diagnosis
- Abstract
Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment provides a comprehensive and concise visual reference on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) seen in children and adults. This book addresses all aspects of AML and ALL including their risk factors, cytogenetics and mutational characteristics, diagnoses, clinical management and prognoses which are imperative and challenging for medical students, residents, hematology and medical oncology fellows, and even community oncologists and hematologists. It presents complex information relying predominantly on pictorial depictions rather than traditional text in a visually instructive format. It replaces the wordiness of a traditional textbook with original and adapted illustrations, instructive schemata and diagrams, photomicrographs, tables, detailed figure legends, and practical, ‘bite-sized'text. The result is a visually engaging book that is easy to read, review, and remember.Crafted by world experts in the field, this digestible volume provides you with the must-know information that you can utilize when encountering AML and ALL patients who require immediate attention. Whether you are an early-career practitioner looking for quick guidance to managing a deadly disease or you are a seasoned clinician looking for a quick review of treatment protocols, this engaging format provides a unique and ‘go-to'resource.Key Features:Contains over 40 tables and over 220 illustrations, histologic photomicrographs, flow diagrams, graphs, and schemata with detailed figure legendsPresents complex scientific aspects such as cytogenetics and molecular mutations in a visually digestible and easy-to-understand formatProvides helpful and evidence-based treatment recommendations when providing induction therapy, consolidation therapy, and bone marrow transplantationIncludes unique chapters on managing psychosexual issues accompanying AML and ALL treatment as well as on the FDA drug development and clinical trial design processIncludes digital access to the e-book as well as an online Image Bank
- Published
- 2018
8. Richter transformation post-ibrutinib treatment of relapsed small lymphocytic lymphoma - a case study
- Author
-
Yee, Annabella C, Chai, Kern Y, and Chiruka, Shingi
- Published
- 2019
9. Sven tot het einde
- Author
-
Zwaan, Irene and Zwaan, Irene
- Subjects
- Leukemia--Treatment, Oppositional defiant disorder in children--Treatment, Oppositional defiant disorder in children
- Abstract
Als Sven op 16-jarige leeftijd bij Ambiq wordt geplaatst, lijkt hij een'gewone'jeugdzorgcliënt. Hij heeft een licht verstandelijke beperking, en daarnaast is bij een psychiatrisch onderzoek gebleken dat hij ODD heeft; een stoornis die leidt tot moeilijk en tegendraads gedrag. Hij woont vanaf zijn twaalfde niet meer thuis. Zijn moeder kan niet voor hem zorgen en zijn vader is pas sinds enkele jaren in beeld. Op de groep voor Zeer Intensieve Behandeling bij Ambiq lijkt hij na een rumoerige start eindelijk zijn plek te vinden. Hij is gemotiveerd om te werken aan zijn ultieme doel: zelfstandig wonen als hij achttien wordt. Dan, als hij zeventien-en-een-half is, krijgt hij leukemie. Ineens zijn er allerlei praktische en ethische kwesties aan de orde. Het team besluit Sven niet te laten vallen en alles te doen binnen hun mogelijkheden om hem een waardig levenseinde te bezorgen. De casus van Sven toont professionals het belang van: - doen wat nodig is, ook al is daar enig kunst- en vliegwerk voor nodig; - bieden van continuïteit en bescherming; - betrekken van familie, ook als dat lastig is; - zorgen voor veiligheid en vertrouwen, voor het kind, maar ook voor de professionals; - het persoonlijke en het professionele met elkaar mogen verenigen; - werken aan een veilig en steunend team; - onvoorwaardelijke steun van de organisatie. Sven tot het einde laat zien wat kinderen die niet meer thuis kunnen wonen werkelijk nodig hebben. Sven doet een beroep op het hart van de professionals om hem heen, en als ze dat laten spreken verdwijnt zijn gedragsstoornis als sneeuw voor de zon. Wonder boven wonder leeft hij maanden langer dan de artsen hadden verwacht. De openhartige verhalen van professionals en familie worden aangevuld met korte uitleg van begrippen in kaders. Zo ontstaat een boeiend en leerzaam praktijkvoorbeeld voor jeugdhulpverleners (in opleiding).
- Published
- 2016
10. KMT2A-MLLT3 AML masquerading as JMML may disguise fatal leukemia
- Author
-
Saad, Ashraf Abdullah, Beshlawi, Ismail, Zachariah, Mathew, and Wali, Yasser
- Published
- 2019
11. Stem cell transplants
- Author
-
Lindsay, Toni
- Published
- 2017
12. Chronic lymphocytic leukaemia: An updated approach to diagnosis and management in general practice
- Author
-
Tomlinson, Ross
- Published
- 2017
13. Impact of aberrant myeloid antigen expression on outcomes of patients with t-cell acute lymphoblastic leukemia
- Author
-
Al-Zaabi, Mohamed, Al-Khabori, Murtadha, Fawaz, Naglaa, Al-Lamki, Sulayma, Al-Riyami, Arwa, Al-Huneini, Mohammed, Al-Muslahi, Muhanna, and Alkindi, Salam
- Published
- 2017
14. Systematic review of the tools used to assess the informational and practical needs of acute leukaemia and lymphoma survivors
- Author
-
Taylor, Karen and Monterosso, Leanne
- Published
- 2016
15. Leukemia and Related Disorders : Integrated Treatment Approaches
- Author
-
Elihu H. Estey, Fred R. Appelbaum, Elihu H. Estey, and Fred R. Appelbaum
- Subjects
- Blood--Diseases--Treatment, Leukemia--Treatment
- Abstract
From the world renowned Fred Hutchinson Cancer Research Center, this book is written for all physicians who treat patients with acute or chronic leukemias or myelodysplasia. It is designed to answer questions about treatment approaches that commonly arise in day-to-day practice. In keeping with the Center's groundbreaking research in bone marrow transplantation, the book provides exceptional coverage of the role of allogeneic transplant in treatment. It also addresses the important issues of supportive care and long-term complications of successful treatment. •Edited and written by experts at the Fred Hutchinson Cancer Research Center•Clinically focused and comprehensive coverage of treatment approaches•Allogeneic transplant addressed in detail•Separate chapters on supportive care and long-term complications
- Published
- 2012
16. Fetal Liver Transplantation
- Author
-
J.-L. Touraine, R.P. Gale, V. Kochupillai, J.-L. Touraine, R.P. Gale, and V. Kochupillai
- Subjects
- Fetal liver cells--Transplantation, Aplastic anemia--Treatment, Leukemia--Treatment, Anemia, Aplastic--therapy, Bone Marrow--transplantation, Fetus--surgery, Hematopoietic Stem Cells, Leukemia, Myelocytic--therapy, Liver--transplantation
- Published
- 2012
17. New Approaches to the Treatment of Leukemia
- Author
-
Emil J. Freireich and Emil J. Freireich
- Subjects
- Leukemia--Treatment, Leukemia--therapy
- Abstract
The European School of Oncology came into existence to respond to a need for informa tion, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universi ties to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice.
- Published
- 2012
18. Acute Leukemias II : Prognostic Factors and Treatment Strategies
- Author
-
Thomas Büchner, Günther Schellong, Wolfgang Hiddemann, Jörg Ritter, Thomas Büchner, Günther Schellong, Wolfgang Hiddemann, and Jörg Ritter
- Subjects
- Leukemia--Prognosis, Leukemia--Treatment, Leukemia--therapy--congresses, Prognosis--congresses
- Abstract
Acute leukemia a quite homogenous disease failed to break through the sound barriere of when untreated reveals a substantial hetero unsatisfactory cure rates even in special sub geneity in its response to therapy. While cure groups. While new protocols including more is achieved in a certain proportion of pa effective supportive care show some increase tients other cases prove to be highly resis in the initial response rates and certain im tant. The curability is superior in acute provements in the long-term results, no ben lymphoblastic (ALL) than in acute myeloid eficial effect on the relapse rate during the (AML) leukemia and - within both type- first 1 Y2 years emerged from any of these higher in children as compared to adults. regimens. Thus, high chances for cure are The two age groups and cell types can be presently restricted to children with ALL further subdivided into prognostic groups and to lesser proportions children with by special diagnostic features. Thus, in AML and adults with ALL and AML.
- Published
- 2012
19. Next-generation cell-based therapies the potential of iPSCs
- Author
-
Kelly, Kilian
- Published
- 2017
20. Diagnosis and management of acute promyelocytic leukemia in an active duty Air Force space operator
- Author
-
Eovaldi, Benjamin, Albaugh, Harry, Hyman, John, and Greenwald, Daniel
- Published
- 2014
21. Understanding Leukemias, Lymphomas and Myelomas
- Author
-
Mughal, Tariq I., Mughal, Sabena T., Goldman, J. M., Mughal, Tariq I., Mughal, Sabena T., and Goldman, J. M.
- Subjects
- Lymphomas, Leukemia, Leukemia--Diagnosis, Lymphomas--Diagnosis, Leukemia--Treatment
- Abstract
A practical and highly illustrated guide to the hematologic cancers, Understanding Leukemias, Lymphomas and Myelomas is an invaluable primer for everyone involved with these conditions, from specialists in training to interested patients. Using straightforward terminology and extensive color figures to describe and illustrate the current procedures
- Published
- 2007
22. Stem Cell Transplantation for Hematologic Malignancies
- Author
-
Robert J. Soiffer and Robert J. Soiffer
- Subjects
- Hematopoietic stem cells--Transplantation, Lymphomas--Treatment, Multiple myeloma--Treatment, Leukemia--Treatment
- Abstract
A comprehensive survey of the current state-of-the-art in hematopoietic stem cell transplantation for malignant disease. The authors focus on the indications and results of transplantation for acute leukemia, chronic myelogenous leukemia, lymphoma, multiple myeloma, and breast cancer. Special attention is given to transplant-related complications, including the pathophysiology and clinical consequences of acute and chronic GVHD, delayed immune reconstitution leading to infectious complications, and organ damage to the lung and liver. Additional chapters address the sources of stem cells and the effects of graft manipulation used to eliminate residual contaminating tumor cells in autologous transplantation, or to reduce the number of T lymphocytes causing GVHD in allogenic transplantation.
- Published
- 2004
23. Functional characterization and multi-factor analysis of exhaustion in chronic lymphocytic leukemia T cells
- Author
-
Lee, Joanne Haeun
- Subjects
Leukemia--Treatment ,HTLV (Viruses) ,Chronic lymphocytic leukemia ,Antigens--Receptors ,Biomedical engineering - Abstract
Adequate cell production for adoptive cell transfer therapies such as Chimeric Antigen Receptor (CAR)-T cell therapy remains a critical barrier to treatment for indications that fail to achieve clinical success. One such disease is Chronic Lymphocytic Leukemia (CLL), a B-cell lymphoma with their characteristically exhausted T cells, marked by a progressive loss of the ability to secrete cytokines and proliferate, as well as an increase in the expression of checkpoint inhibitor molecules such as PD-1. The goal of this thesis is to characterize the functional differences or specific biomarkers within the CLL patient population that is indicative of the proliferation outcomes. Conventional clinical markers such as Rai stage or PD-1 expression alone were inadequate to describe the complex variability among patients. In order to better characterize exhaustion using microscopy-based cell function assays, we developed a sample sparing microscopy chamber that requires as little as 1000 cells per sample. The microscopy chambers were mass produced via injection molding, and made compatible with the antibody microcontact printing technique developed in the Kam lab. The chambers typically reduced cell usage per experiment by 20-fold. This reduction allowed us to measure IL-2 secretion, T cell arrest response to activating antibody patterns (pattern alignment), and motility of scarce human samples simultaneously from a single experiment. Results from these functional readouts along with other clinical markers were used as inputs for a multifactor exploratory analysis to cluster patients according to their functional similarities from the combination of responses in an unbiased manner. The resulting clusters based on the combination of the top 3 parameters IL-2, pattern alignment, and PD-1 resulted in better separation of patient groups and provided a basis for predicting max doubling outcomes from these inputs. We further used motility measurements as a way to understand initial T cell response to activation before the stop response, which was measured as pattern alignment previously. The time it takes for cells to come to a stop at the signal was most informative for translating T cell activation response to a stop response, and eventually to downstream effector functions of cytokine secretion and proliferation. The results of this work provide a powerful framework to describe different donors, and can be applied to cells from additional donors to guide future cell expansion studies.
- Published
- 2021
- Full Text
- View/download PDF
24. Trial and Error: The Invention of Cancer Chemotherapy 1950-1980
- Author
-
Levy, Moran
- Subjects
History ,Leukemia--Treatment ,Oncology ,Social sciences--Research ,Chemotherapy - Abstract
Between the mid-1940s and the mid-1970s oncology turned from a marginalized experimental field into one of the most dominant medical specialties in the United States. Cancer chemotherapy, once a controversial practice, became a standard therapy alongside surgery and radiation. The success of cancer chemotherapy, however, is not so simple to explain. Cancer chemotherapy was adopted despite broad and evident dissatisfaction with its limited clinical achievements, common among patients and doctors alike. To explain the success of cancer chemotherapy, this dissertation examines the social processes that allowed for the emergence and stabilization of a new therapeutic field. I show that common sociological approaches for studying medical experts, such as the sociology of the professions and medicalization theories, fail to provide a convincing explanation for the emergence of chemotherapy because they assume the existence of professional entities or a set of tasks and problems as pre-given facts. Alternatively, I build on these approaches to show that oncology itself, as well as the tasks and problems of cancer medicine, evolved with the invention of the new therapeutic technologies of cancer chemotherapy. I argue that when cancer chemotherapists, a nascent professional group, failed to deliver on their promise for a cancer cure in the 1940s, they began exploring what cancer chemotherapy might become. During the following decades, they gradually reinvented the diagnostic categories, clinical methods and therapeutic objectives of oncology, thus establishing a new mode of therapeutic intervention. The dissertation further examines the tactics and resources that contributed to the success of these efforts and to the stabilization of the new therapy. I trace how oncologists leveraged limited clinical achievements to (a) legitimate their practices and frame experimental outcomes as therapeutic objectives and (b) assemble the infrastructure and alliances needed to expand the enterprise and improve on existing clinical practices and results. The first paper ‘Adequate Trials: How the Search for a Cure Shaped Leukemia Diagnosis?’ addresses the rewriting of the diagnosis of leukemia, to demonstrate that the success of chemotherapy depended on the ability to transform the categories used to classify cancers and patients. Mobilizing bureaucratic capacities and redefining their ethical commitments, oncologists managed to allocate the ‘right patients’ to the ‘right trials,’ reshuffling existing diagnostic classifications, so that the conditions under which drugs could ‘work’ might be created. The second paper ‘From Bullets to Cocktails: The Invention of New Therapeutic Methods in Cancer Chemotherapy’ explains how oncologists sheltered themselves from the external demands of patients and regulators to secure space for experimentation with controversial procedures of combination therapy. The paper traces the epistemic, institutional and ethical resources mobilized by oncologists to articulate their research agendas as problems for basic science, thus establishing alliances within the National Institute of Health. The third paper, ‘How Means Turn to Ends: A Pragmatist Account of the Rise of Oncology’ addresses the normative legitimation of the objectives of chemotherapy to demonstrate that the framing of new experimental categories in terms of community-based clinical care was a key to the success of oncology. Together, the three papers demonstrate that to make medical drugs ‘work’ (i.e., produce predictable effects that are commonly seen as therapeutically valuable), oncologists had to restructure the practices, institutions, classifications, objectives, and roles in cancer research and clinical care. The dissertation thus suggests that an analytical focus on the invention of new modes of therapeutic intervention would provide valuable insights into questions central to a wide range of sociological investigations. The invention of therapeutic technologies offers a lens for exploring the transformation of the institutions and practices of the medical profession, biomedical research, drug regulation and healthcare.
- Published
- 2020
- Full Text
- View/download PDF
25. Antibodies: Antibodies as Therapeutics
- Author
-
Williamson, Susan
- Published
- 2010
26. Be Brave and Shave
- Published
- 2008
27. Bridging the Gap Between Our Understanding of AML Pathogenesis and the Development of Targeted Therapies
- Author
-
Tavakkoli, Montreh
- Subjects
Leukemia--Treatment ,Acute myeloid leukemia ,Oncology ,Carcinogenesis ,Epidemiology ,hemic and lymphatic diseases - Abstract
Acute myeloid leukemia (AML) is the most common acute leukemia diagnosed in the U.S., with an annual incidence of ~15,000 per year. The median age of diagnosis is 67 years, however, AML afflicts individuals of all ages. Within the past 4 decades, only modest improvements have been made in the treatment of AML. However, the advent of DNA sequencing technologies, fluorescence-activated cell sorting, flow cytometry, and immunodeficient murine models have significantly improved our understanding of the molecular and cellular changes that promote the development of AML. The purpose of my thesis is to explain our current understanding of malignant transformation in AML, and to describe how this knowledge has aided the clinical assessment and treatment of this disease. In order to demonstrate this, I will provide an introduction to the epidemiology and clinical manifestations of AML, the molecular mechanisms underlying its pathogenesis, and new methods to risk-stratify and treat the disease. I will then provide a thorough discussion on normal hematopoiesis and the cellular mechanisms of AML pathogenesis (in the context of the cancer stem cell theory), and will conclude with a brief summary on a novel leukemic stem cell-directed therapy that we are currently developing in our laboratory. For the first time in over 40 years, drastic changes are underway in the way we evaluate and treat AML.
- Published
- 2014
- Full Text
- View/download PDF
28. Correcció del biaix en estudis observacionals amb el Propensity Score. Aplicació a l'estimació de l'efecte del tractament de la leucèmia
- Author
-
Morgades de la Fe, Mireia, Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa, Cobo Valeri, Erik, and Ribera Santasusana, Josep Mª
- Subjects
Leukemia--Treatment ,estudis observacionals ,leucèmia ,quimioteràpia ,Matemàtiques i estadística::Matemàtica aplicada a les ciències [Àrees temàtiques de la UPC] ,Leukemia--Palliative treatment ,alo-trasplantament ,Propensity Score ,Terapèutica -- Mètodes estadístics ,Leukemia--Chemotherapy--Evaluation ,92 Biology and other natural sciences::92C Physiological, cellular and medical topics [Classificació AMS] - Abstract
Volem analitzar l’efecte del tractament (quimioteràpia o alo-trasplantament) de la leucèmia aguda limfoblàstica (LAL) d’alt risc en adults mitjançant un estudi observacional. La limitació més important dels estudis observacionals és que l’assignació dels malalts al tractament no es realitza de manera aleatòria, la qual cosa provoca que existeixi un biaix de selecció per indicació de tractament. Al 1983, Rosembaum i Rubin (1) proposen un nou mètode, el Propensity Score (PS), per tal de controlar aquest tipus de biaix en els estudis observacionals. Mitjançant simulació i per a diferents escenaris, analitzem l’eficàcia del Propensity Score introduït com a variable d’ajustament en el model de Cox. L’estimació delPropensity Score es duu a terme mitjançant models lineals generalitzats (MLG) o reproduint el criteri clínic, el qual està protocolitzat per assignació binària. De la simulació obtenim que, per a l’únic escenari que presenta confusió, la millor estimació de l’efecte del tractament es dóna quan ajustem pel Propensity Score assignat de manera binària. Per a la resta d’escenaris proposats, s’obtenen biaixos de l’estimació del tractament tot ells molt petits i similars sigui quin sigui l’ajustament realitzat. Els mateixos resultats obtenim quan simulem mostres de grandària petita. En conclusió, per als diferent models estudiats mitjançant simulació, demostrem que la millor correcció del biaix la proporciona el Propensity Score, en particular, emprat de manera binària inclús quan la mostra és petita. Emprant aquest ajustament en les dades clíniques, obtenim que els malalts que fan alo-trasplantament tenen un risc de morir entre [0,611; 2,711] respecte als malalts que fan quimioteràpia, la qual cosa ens indica que no hi ha diferències estadísticament significatives entre ambdós grups de malalts tractats.
- Published
- 2008
29. Studies on the anti-tumor effects of conjugated fatty acids on murine macrophage-like leukemia cells.
- Author
-
Liu, Wai Nam., Chinese University of Hong Kong Graduate School. Division of Life Sciences., Liu, Wai Nam., and Chinese University of Hong Kong Graduate School. Division of Life Sciences.
- Abstract
白血病由血液或骨髓中的癌細胞所形成,基於其造血幹細胞(HSC)的增殖和分化出現偶聯或不平衡的情況而產生的結果。白血病是香港最常見的兒童癌症,報告指出,於2005年至2009年期間,平均每年約有270名患者死於該病。傳統治療白血病的方法包括化療,放射性治療,骨髓或外周血幹細胞移植,至於採用哪種療法,則要視乎白血病的類型和階段。然而,這些療法會為患者帶來各種副作用,因此,在過去十年間,研發新型治療白血病的藥物引起了越來越多人的關注。, 共軛脂肪酸(CFA),是指一群位置及幾何異構體的多元不飽和脂肪酸(PUFA),於它們的化學結構中,最少有一組共軛雙鍵。天然的共軛脂肪酸包括,存在於反芻動物的肌肉及乳製品中的共軛雙烯酸(CLA),存在於植物種子油中的共軛三烯酸(CLN),以及存在於海藻中的共軛四烯酸,共軛五烯酸(CEPA)和共軛六烯酸(CDHA)。過往的研究證實了共軛雙烯酸擁有各種生理及醫藥功效,包括抗脂肪分化,抗動脈硬化,抗糖尿病,免疫調節和抗腫瘤作用。根據體外實驗報告指出,共軛三烯酸和共軛四烯酸對多種腫瘤細胞株皆具有生長抑制作用,然而,它們對小鼠巨噬細胞樣的白血病細胞之調節作用和機制仍有待研究。因此,在這篇論文中,共軛三烯酸和共軛四烯酸對小鼠巨噬細胞樣的白血病細胞的抗增殖作用,以及它們引起的相關機制將會被探討。, 本實驗計劃研究了九個不同的多元不飽和脂肪酸異構體對小鼠巨噬細胞樣的白血病細胞PU5-1.8細胞的抗增殖能力,當中包括三烯酸、四烯酸、共軛雙烯酸、共軛三烯酸和共軛四烯酸的異構體。結果清楚地表明,共軛三烯酸和共軛四烯酸異構體皆能對白血病細胞表現出劑量依賴性的生長抑制作用。於十個異構體當中,順式-8,反式-10,順式-12共軛三烯酸(蘭花酸)和順式-9,反式-11,反式-13,順式-15共軛四烯酸(杷茬酸)較其他共軛脂肪酸異構體更有效抑制白血病細胞的生長,因此,他們被選定為主要的研究對象,以便對它們所引起的相關機制作進一步了解。此外,蘭花酸和杷茬酸對其他小鼠巨噬細胞樣的白血病細胞,包括J774 A.1細胞和P388D1細胞,也具備抗增殖作用,表現其生長抑制作用並不是純粹針對單一種腫瘤細胞株的。有趣的是,蘭花酸和杷茬酸對PU5-1.8細胞的生長抑制作用是可以局部逆轉的,但只限以低濃度的共軛脂肪酸培養白血病細胞以及培養的時間不多於24小時,否則,隨著培養的時間增加或共軛脂肪酸的濃度增加時,該生長抑制作用幾乎是不可逆轉的。另一方面,結果也表明蘭花酸和杷茬酸在其抑制白血病細胞增殖率為五十百分比之濃度下,它們對腫瘤細胞以及小鼠正常細胞的毒性作用是很少的。除了在體外研究,預先以蘭花酸處理的PU5-1.8細胞於BALB/c小鼠內導致白血病細胞生長的能力也以劑量依賴方式被抑制。, 幾種不同的機制也能解釋蘭花酸和杷茬酸對PU5-1.8細胞的生長抑制能力,當中包括阻礙腫瘤細胞週期的前進,增加腫瘤細胞內活性氧(ROS)的生產或誘導腫瘤細胞的凋亡。研究結果指出,蘭花酸和杷茬酸可以抑制PU5-1.8細胞週期的進程並將其停留在G₀/G₁時相,換來的是減少處於S時相的細胞的比例。此外,透過西方蛋白質印跡分析,細胞週期蛋白E的表達有所下調,同時,幾個細胞週期調控蛋白的表達,包括p21,p27及p53蛋白則被上調,跟上述的實驗結果吻合。此外,經蘭花酸和杷茬酸處理後,PU5-1.8細胞內的ROS濃度和線粒體質量也有所增加,而它們對白血病細胞的生長抑制作用則會被抗氧化劑所減弱,這一點說明了蘭花酸和杷茬酸對PU5-1.8細胞的抗增殖作用可能與細胞內的脂質過氧化物濃度和線粒體質量有關。最後,通過各種測試細胞凋亡的實驗,包括利用細胞死亡檢測的ELISA{U+1D3E}{U+1D38}{U+1D41}{U+1D40}試劑盒,Annexin-V和JC-1染色等方法,清楚地表明了蘭花酸和杷茬酸能誘導PU5-1.8細胞的凋亡。加上西方蛋白質印跡分析,PU5-1.8細胞內Bcl-2和Bcl-XL的蛋白的表達水平有所下降,而相反Bax蛋白的表達水平則有所提升,足以證明蘭花酸和杷茬酸能引發PU5-1.8細胞的凋亡。, 總括來說,蘭花酸和杷茬酸對PU5-1.8細胞的抗增殖作用呈現時間和劑量依賴性,該作用可能基於阻礙腫瘤細胞週期的前進,增加腫瘤細胞內ROS的生產或誘導腫瘤細胞的凋亡。由於蘭花酸和杷茬酸分別在植物種子油和海藻的含量相當高,再加上它們對正常細胞無直接毒性,若果能夠對它們的抗腫瘤作用以及其分子機制有更透徹的理解,它們有望發展成為未來治療白血病的藥物。, Leukemia is a cancer of the blood or bone marrow which is the result of uncoupling or imbalance of the proliferation and differentiation of hematopoietic stem cells (HSC). It is the most common childhood cancer in Hong Kong and it claims the lives of around 270 patients per year from 2005 to 2009 in average. Conventional approaches to leukemia therapy include chemotherapy, radiotherapy and bone marrow or peripheral blood stem cell transplantation, depending on the types and stages of leukemia. Nevertheless, these therapies are accompanied by a number of undesirable effects to the patients, hence, the development and research in novel treatments of leukemia are attracting increasing attention in the past decades., Conjugated fatty acids (CFA) refer to the positional and geometric isomers of polyunsaturated fatty acids (PUFA) with conjugated double bonds. Naturally-occurring CFA include conjugated linoleic acids (CLA) from meat and dairy products of ruminant animals, conjugated linolenic acids (CLN) from plant seed oils, conjugated tetraenoic acids, conjugated eicosapentaenoic acids (CEPA) and conjugated docosahexaenoic acids (CDHA) from seaweeds. CLA have been shown to possess various biological and pharmacological activities, including anti-adipogenic, anti-atherogenic, anti-diabetogenic, immunomodulatory and anti-tumor effects. Furthermore, previous researches have demonstrated the growth-inhibitory effects of CLN and conjugated tetraenoic acids on a wide variety of cancer cell lines in vitro, however, their modulatory effects and action mechanisms on murine macrophage-like leukemia cells remain poorly understood. In this thesis project, the anti-proliferative effects of CLN and conjugated tetraenoic acids on the murine macrophage-like leukemia cells, as well as their action mechanisms will be elucidated., Nine different PUFA isomers, including linolenic acid, tetraenoic acid, CLA, CLN and conjugated tetraenoic acids were examined for their anti-proliferative effects on the murine macrophage-like leukemia PU5-1.8 cells. The results clearly showed that all CLN isomers and cis-parinaric acid could exhibit growth-inhibitory effects on the leukemia cells in a dose-dependent manner. It was found that jacaric acid and cis-parinaric acid were relatively more potent than the other isomers used in the present study, hence, they were chosen to be the specific targets for more in-depth mechanistic studies. In addition, the anti-proliferative effects of jacaric acid and cis-parinaric acid were observed in other murine macrophage-like leukemia cell lines, including J774 A.1 cells and P388D1 cells, suggesting that the effects were not cell-line specific. Interestingly, the growth-inhibitory effects were partially reversible at lower concentrations of CFA used within 24 hours of incubation, but the effects were almost irreversible when either the incubation time or the concentration of CFA used was increased. Furthermore, the results showed that both jacaric acid and cis-parinaric acid at their IC₅₀ growth-inhibitory concentrations on PU5-1.8 cells exerted minimal, if any, direct cytotoxic effects on the tumor cells as well as the murine normal cells. Apart from the in vitro studies, it was also demonstrated that pre-treatment of PU5-1.8 cells with jacaric acid could significantly decrease the leukemic cell growth in syngeneic BALB/c mice in a dose-dependent manner., Several mechanisms were proposed for the anti-proliferative effects of jacaric acid and cis-parinaric acid on PU5-1.8 cells, including the triggering of cell cycle arrest, increasing the production of intracellular reactive oxygen species (ROS) or induction of apoptosis in the tumor cells. The results showed that jacaric acid and cis-parinaric acid could inhibit the cell cycle progression since an accumulation of PU5-1.8 cells at the G₀/G₁ phase was observed, together with a decrease in the cell population at the S phase. This finding was supported by the down-regulation of cyclin E protein and up-regulation of several cell cycle regulatory proteins, including the p21, p27 and p53 proteins. Apart from that, the intracellular ROS concentration and the mitochondrial mass were found to be increased in jacaric acid- or cis-parinaric acid-treated PU5-1.8 cells, and their growth-inhibitory effects were alleviated after the addition of antioxidants. Therefore, the anti-proliferative effects of jacaric acid and cis-parinaric acid on PU5-1.8 cells might be correlated with the intracellular concentration of lipid peroxides and the mitochondrial mass. Furthermore, the results clearly demonstrated that both jacaric acid and cis-parinaric acid exhibited dose-dependent apoptosis-inducing effects on PU5-1.8 cells, as revealed by the Cell Death Detection ELISA{U+1D3E}{U+1D38}{U+1D41}{U+1D40} kit, annexin V assay and JC-1 dye staining method. In addition, it was found that the expression levels of Bcl-2 and Bcl-xL proteins were decreased, whereas the expression level of Bax protein was increased in PU5-1.8 cells, further confirming that apoptosis occurred in PU5-1.8 cells after treatment with jacaric acid and cis-parinaric acid., Collectively, the results showed that jacaric acid and cis-parinaric acid could exhibit their anti-proliferative effects on PU5-1.8 cells in a time- and dose-dependent manner, through the triggering of cell cycle arrest, increasing the production of intracellular ROS or induction of apoptosis in the tumor cells. Owing to their high abundance in plant seed oils and seaweeds, and being relatively non-cytotoxic, they might be potential candidates for the treatment of leukemia. Further investigations are required in order to develop a better understanding on the molecular action mechanisms underlying the anti-tumor effects of jacaric acid and cis-parinaric acid on leukemia cells before they could be developed as the therapeutic drugs for leukemia., Detailed summary in vernacular field only., Liu, Wai Nam., Thesis (M.Phil.)--Chinese University of Hong Kong, 2012., Includes bibliographical references (leaves 169-182)., s also in Chinese., p.i, 摘要 --- p.v, Acknowledgements --- p.viii, List of Abbreviations --- p.ix, List of Figures and Tables --- p.xiii, Publications --- p.xvii, Chapter Chapter 1 --- General introduction, Chapter 1.1 --- Introduction to hematopoiesis and leukemia --- p.1, Chapter 1.1.1 --- Introduction to hematopoiesis --- p.1, Chapter 1.1.2 --- Introduction to leukemia --- p.7, Chapter 1.1.2.1 --- Classification of leukemia --- p.7, Chapter 1.1.2.2 --- Epidemiology of leukemia --- p.10, Chapter 1.1.2.3 --- Conventional approaches to leukemia therapy --- p.12, Chapter 1.1.2.4 --- Alternative approaches to leukemia therapy --- p.17, Chapter 1.2 --- Introduction to conjugated fatty acids --- p.19, Chapter 1.2.1 --- An overview of polyunsaturated fatty acids and conjugated fatty acids --- p.19, Chapter 1.2.2 --- Chemical structures and physical properties of CLN and conjugated tetraenoic acids --- p.21, Chapter 1.2.3 --- Natural occurrence of CLN and conjugated tetraenoic acids --- p.26, Chapter 1.2.4 --- Synthesis of CLN and conjugated tetraenoic acids --- p.28, Chapter 1.2.5 --- Metabolism of CLN --- p.30, Chapter 1.2.6 --- Major biological and pharmacological activities of CLN and conjugated tetraenoic acids --- p.30, Chapter 1.2.6.1 --- Anti-obese and hypolipidemic property --- p.31, Chapter 1.2.6.2 --- Anti-carcinogenic property --- p.32, Chapter 1.2.6.2.1 --- Anti-proliferative effect --- p.32, Chapter 1.2.6.2.2 --- Apoptosis-inducing effect --- p.33, Chapter 1.3 --- Aims and scopes of this thesis --- p.36, Chapter Chapter 2 --- Materials and methods, Chapter 2.1 --- Materials --- p.39, Chapter 2.1.1 --- Animals --- p.39, Chapter 2.1.2 --- Cell lines --- p.39, Chapter 2.1.3 --- Cell culture media and reagents --- p.40, Chapter 2.1.4 --- Fatty acids --- p.44, Chapter 2.1.5 --- Reagents and buffers for flow cytometry --- p.48, Chapter 2.1.6 --- Reagents and buffers for Western blotting --- p.51, Chapter 2.1.7 --- Cell Death Detection ELISA{U+1D3E}{U+1D38}{U+1D41}{U+1D40} kit --- p.60, Chapter 2.2. --- Methods --- p.62, Chapter 2.2.1 --- Culture of tumor cell lines --- p.62, Chapter 2.2.2 --- Isolation and culture of murine normal cells --- p.63, Chapter 2.2.3 --- Determination of cell proliferation by CyQUANT® NF cell proliferation assay --- p.65, Chapter 2.2.4 --- Determination of cell viability --- p.66, Chapter 2.2.5 --- Cytotoxicity test of CFA on normal cells --- p.67, Chapter 2.2.6 --- In vivo tumorigenicity assay --- p.68, Chapter 2.2.7 --- Analysis of cell cycle profile --- p.69, Chapter 2.2.8 --- Measurement of DNA fragmentation by Cell Death Detection ELISA{U+1D3E}{U+1D38}{U+1D41}{U+1D40} kit --- p.70, Chapter 2.2.9 --- Analysis of Annexin V-GFP/PI dual staining profile --- p.71, Chapter 2.2.10 --- Determination of mitochondrial membrane potential by JC-1 staining --- p.72, Chapter 2.2.11 --- Determination of intracellular reactive oxygen species generation --- p.72, Chapter 2.2.12 --- Determination of mitochondrial mass --- p.73, Chapter 2.2.13 --- Protein expression study --- p.74, Chapter 2.2.14 --- Statistical analysis --- p.78, Chapter Chapter 3 --- Studies on the anti-proliferative effects of jacaric acid and cis-parinaric acid on murine macrophage-like leukemia cells, Chapter 3.1 --- Introduction --- p.79, Chapter 3.2 --- Results --- p.82, Chapter 3.2.1 --- Anti-proliferative effects of CFA isomers on murine macrophage-like leukemia PU5-1.8 cells in vitro --- p.82, Chapter 3.2.2 --- Kinetic and reversibility studies of the anti-proliferative effects of jacaric acid and cis-parinaric acid on PU5-1.8 cells --- p.92, Chapter 3.2.3 --- Cytotoxic effects of jacaric acid and cis-parinaric acid on PU5-1.8 cells --- p.97, Chapter 3.2.4 --- Cytotoxic effects of jacaric acid and cis-parinaric acid on murine normal cells in vitro --- p.99, Chapter 3.2.5 --- Effect of jacaric acid on the in vivo tumorigenicity of PU5-1.8 cells --- p.102, Chapter 3.3 --- Discussion --- p.104, Chapter Chapter 4 --- Mechanistic studies on the anti-tumor effects of jacaric acid and cis-parinaric acid on murine macrophage-like leukemia cells, Chapter 4.1 --- Introduction --- p.111, Chapter 4.2 --- Results --- p.117, Chapter 4.2.1 --- Effects of jacaric acid and cis-parinaric acid on the cell cycle profile of murine macrophage-like leukemia PU5-1.8 cells --- p.117, Chapter 4.2.2 --- Effects of jacaric acid and cis-parinaric acid on the expression of cell cycle regulatory proteins in murine macrophage-like leukemia PU5-1.8 cells --- p.121, Chapter 4.2.3 --- Effects of jacaric acid and cis-parinaric acid on the generation of reactive oxygen species in murine macrophage-like leukemia PU5-1.8 cells --- p.124, Chapter 4.2.4 --- Effects of antioxidants on the anti-proliferative effects of jacaric acid and cis-parinaric acid on the murine macrophage-like leukemia PU5-1.8 cells --- p.128, Chapter 4.2.5 --- Effects of jacaric acid and cis-parinaric acid on the mitochondrial mass in murine macrophage-like leukemia PU5-1.8 cells --- p.131, Chapter 4.2.6 --- Effects of jacaric acid and cis-parinaric acid on the induction of apoptosis in murine macrophage-like leukemia PU5-1.8 cells --- p.135, Chapter 4.2.7 --- Effects of jacaric acid and cis-parinaric acid on the induction of phosphatidylserine externalization in murine macrophage-like leukemia PU5-1.8 cells --- p.139, Chapter 4.2.8 --- Effects of jacaric acid and cis-parinaric acid on the mitochondrial membrane potential in murine macrophage-like leukemia PU5-1.8 cells --- p.144, Chapter 4.2.9 --- Effects of jacaric acid and cis-parinaric acid on the expression of apoptosis-regulatory proteins in murine macrophage-like leukemia PU5-1.8 cells --- p.149, Chapter 4.3 --- Discussion --- p.152, Chapter Chapter 5 --- Conclusions and future perspectives, Chapter 5.1 --- Conclusions --- p.161, Chapter 5.2 --- Future perspectives --- p.164, References --- p.169, http://library.cuhk.edu.hk/record=b5549197, Use of this resource is governed by the terms and conditions of the Creative Commons “Attribution-NonCommercial-NoDerivatives 4.0 International” License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
- Published
- 2012
30. Do RARA/PML fusion gene deletions confer resistance to ATRA-based therapy in patients with acute promyelocytic leukemia?
- Author
-
G Nichols, Shivakumar Subramaniyam, Vundavalli V. Murty, Michael A. Weiner, Subhadra V. Nandula, Prakash Satwani, Bachir Alobeid, and Govind Bhagat
- Subjects
Acute promyelocytic leukemia ,Cancer Research ,medicine.drug_class ,RARA/PML Fusion Gene ,Fusion gene ,Promyelocytic leukemia protein ,Tretinoin ,medicine ,Genetics ,In patient ,Retinoid ,Drug resistance in cancer cells ,neoplasms ,Leukemia ,biology ,organic chemicals ,Hematology ,medicine.disease ,Virology ,biological factors ,Leukemia--Treatment ,Oncology ,FOS: Biological sciences ,Cancer research ,biology.protein ,Gene fusion ,medicine.drug - Abstract
Acute promyelocytic leukemia (APL) is characterized by the translocation t(15;17)(q22;q21), resulting in the promyelocytic leukemia (PML)-retinoic acid receptor alpha (RARA) fusion protein in 95% cases whereas variant translocations involving PLZF (11q23), NPM (5q35), NUMA (11q13) and STAT5b (17q23) account for the rest. Leukemias with PML-RARA translocations respond well to all-trans retinoic acid (ATRA) or arsenic trioxide (ATO) therapy whereas those with PLZF-RARA fusions respond poorly. Although primary resistance to ATRA is rare, secondary or acquired resistance is frequently observed in patients treated with ATRA alone or in combination with other chemotherapy regimens. However, molecular abnormalities mediating resistance to ATRA therapy are underexplored. Here, we report two cases of APL with RARA-PML deletions on der(17) or der(15), which displayed clinical evidence of primary and secondary resistance to therapy, respectively.
- Published
- 2006
- Full Text
- View/download PDF
31. Investigations on the anti-leukemia and immunomodulatory effects of Agaricus blazei extracts.
- Author
-
Jiang, Jingjing., Chinese University of Hong Kong Graduate School. Division of Pharmacy., Jiang, Jingjing., and Chinese University of Hong Kong Graduate School. Division of Pharmacy.
- Abstract
No direct stimulation of human peripheral blood mononuclear cells proliferation could be detected with incubation of various AB extracts including JAB80E70 in vitro. However, ex vivo assay performed using BALB/c mice orally fed with either water (control) or JAB80E70 for 28 days indicated for the first time that extract-treated groups significantly lowered the ex vivo mitogen-stimulated lymphocyte proliferation., Our study started with the preparations of different AB extracts using various solvent systems with or without heating. Among all AB extracts tested, the extract JAB80E70 (extracted with 70% v/v ethanol at 80°C) showed the strongest selective suppression on the growth of human leukemia NB-4 and K-562 cells. The anti-leukemia effect of JAB80E70 was also confirmed in vivo using xenografted NB-4 bearing athymic nude mice model., Phytochemical studies suggested that the selective anti-leukemia activity of JAB80E70-W-B-1 was retained in a relatively polar sub-fraction. One compound was isolated and identified as adenosine from JAB80E70-W-B-1. To the best of our knowledge, this is the first report of the presence of adenosine in AB, even though it exhibited no anti-leukemia activity in vitro., The mushroom Agaricus blazei (AB) is traditionally used as a remedy against various cancers, infections and immune-related diseases. In the present study, the underlying mechanisms of the anti-tumor and immunomodulatory effects of AB extracts on human leukemia cells were systematically investigated., With bioassay-guided fractionation, a sub-fraction (JAB80E70-W-B-1) with almost 5-fold improved selective cytotoxicity towards NB-4 cells was obtained. Both JAB80E70 and JAB80E70-W-B-1 could induce apoptosis characteristic DNA fragmentation and nucleosomes enrichment in NB-4 cells. An increase in the pro-apoptotic and a decrease in the anti-apoptotic Bcl-2 family proteins expression were observed in NB-4 cells treated with JAB80E70-W-B-1. JAB80E70-W-B-1 was also found to enhance activities of caspases 3, 8 and 9 in NB-4 cells. However, the activation of caspases 3 and 9 was not affected by the inhibition of caspase 8. Furthermore, JAB80E70-W-B-1 induced apoptosis in NB-4 cells was accompanied by a significant reduction in mitochondria membrane potential and telomerase activity. These results demonstrated that JAB80E70-W-B-1 induced apoptosis in NB-4 cells was dependent on caspase activity, and involved multiple molecular pathways., Jiang, Jingjing., Adviser: Lau Bik San Clara., Source: Dissertation Abstracts International, Volume: 70-06, Section: B, page: 3454., Thesis (Ph.D.)--Chinese University of Hong Kong, 2008., Includes bibliographical references (leaves 224-250)., Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web., Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web., s in English and Chinese., School code: 1307., isbn: 9781109226621, Use of this resource is governed by the terms and conditions of the Creative Commons “Attribution-NonCommercial-NoDerivatives 4.0 International” License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
- Published
- 2008
32. Isolation, characterization, evaluation and mechanistic study of the antiproliferation fractions from shiitake (Lentinula edodes) exudates towards HL60 (acute promyelocytic leukemia) cell line.
- Author
-
Guo, Yuming., Chinese University of Hong Kong Graduate School. Division of Biology., Guo, Yuming., and Chinese University of Hong Kong Graduate School. Division of Biology.
- Abstract
In this study, a novel compound was isolated and purified from the solid culture medium (potato dextrose agar) of shiitake 1358 strain through series of methods, such as ethanol precipitation, macroporous resin column separation, semi-preparative high performance liquid chromatography separation and preparative thin-layer chromatography separation. Analyzing spectra from fourier transform infra-red spectroscopy, gas chromatography-mass spectrometry, 1-dimension and 2-dimension nuclear magnetic resonance, the chemical structure of the novel compound was determined and named as 4-amino-5,6-dihydrobenzo[d]oxonine-2,7(1H,4H)-dione. It could inhibit the proliferation of HL-60 leukemia cells significantly and with an IC50 of 1.56 mug/ml (7.123 mumol/L) in the 72-hour treatment. From the results, it is suggested that this compound could activate the G2 phase checkpoint control of the cell cycle to arrest the cell cycle in G2 phase. In addition, it could suppress the replicative DNA synthesis to inhibit the proliferation of HL-60 leukemia cells. The more important is that this compound can induce the apoptosis of HL-60 leukemia cells significantly through intrinsic and extrinsic apoptotic pathways. The compound could induce intrinsic and extrinsic apoptosis through the regulation of the apoptosis-related proteins, such as Fas ligand, Bax, Bcl-2, Caspase 8, Caspase 9, and Caspase 3. For intrinsic pathway, the compound might upregulate Bax, downregulated Bcl-2, activated the Caspase 9, subsequently activated Capase 3, and ultimately led to cell death. For extrinsic pathway, the compound upregulated the Fas ligand, cleaved and activated Procaspase 8 to active Caspase 8, further cleaved and activated Procaspase 3 to active Caspase 3 to commit the cells to apoptosis., Leukemia is a malignant cancer that involves the bone marrow and blood circulation systems. Leukemia results in the uncontrolled growth of abnormal (leukemic) white blood cells and may also invade other organs, including the liver, spleen, lymph nodes, testes, and brain. In 2007, about 44,240 new cases of leukemia were diagnosed and 21,790 patients died from all types of leukemias in USA., Shiitake was first cultivated in China more than 800 years ago. It is the second most commonly cultivated edible mushrooms in the world nowadays. For a long time, shiitake has been valued for its unique taste and flavor and as a medicinal invigorant. According to ancient Chinese medicinal theory, consumption of shiitake was in favor of long life and good health. In China and Japan, shiitake has been used as both a food and a medicinal herb for thousands of years. It is the source of several well-studied preparations with proven pharmacological properties, especially the polysaccharide lentinan. Currently, most researches concentrate on the anticancer activities of the extracts from the fruiting body of shiitake, especially polysaccharides. Report about the anti-cancer effects of other components from the shiitake mushroom is scarce. The objectives of this investigations were: (1) to study the anticancer activities of brownish substances obtained during the solid medium culture of shiitake on specific cancer cell unes, especially HL60 cancer cell line; (2) to isolate and characterize the active compound(s) in the brown mushroom exudates; and (3) to propose the possible mechanism of actions, especially the function of the bcl-2 family genes and proteins., by Guo, Yuming., Adviser: Chung Hale Yin., Source: Dissertation Abstracts International, Volume: 70-06, Section: B, page: 3314., Thesis (Ph.D.)--Chinese University of Hong Kong, 2008., Includes bibliographical references (leaves 188-199)., Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web., Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web., s in English and Chinese., School code: 1307., isbn: 9781109226775, Use of this resource is governed by the terms and conditions of the Creative Commons “Attribution-NonCommercial-NoDerivatives 4.0 International” License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
- Published
- 2008
33. Correcció del biaix en estudis observacionals amb el Propensity Score. Aplicació a l'estimació de l'efecte del tractament de la leucèmia
- Author
-
Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa, Cobo Valeri, Erik, Ribera Santasusana, Josep Mª, Morgades de la Fe, Mireia, Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa, Cobo Valeri, Erik, Ribera Santasusana, Josep Mª, and Morgades de la Fe, Mireia
- Abstract
Volem analitzar l’efecte del tractament (quimioteràpia o alo-trasplantament) de la leucèmia aguda limfoblàstica (LAL) d’alt risc en adults mitjançant un estudi observacional. La limitació més important dels estudis observacionals és que l’assignació dels malalts al tractament no es realitza de manera aleatòria, la qual cosa provoca que existeixi un biaix de selecció per indicació de tractament. Al 1983, Rosembaum i Rubin (1) proposen un nou mètode, el Propensity Score (PS), per tal de controlar aquest tipus de biaix en els estudis observacionals. Mitjançant simulació i per a diferents escenaris, analitzem l’eficàcia del Propensity Score introduït com a variable d’ajustament en el model de Cox. L’estimació delPropensity Score es duu a terme mitjançant models lineals generalitzats (MLG) o reproduint el criteri clínic, el qual està protocolitzat per assignació binària. De la simulació obtenim que, per a l’únic escenari que presenta confusió, la millor estimació de l’efecte del tractament es dóna quan ajustem pel Propensity Score assignat de manera binària. Per a la resta d’escenaris proposats, s’obtenen biaixos de l’estimació del tractament tot ells molt petits i similars sigui quin sigui l’ajustament realitzat. Els mateixos resultats obtenim quan simulem mostres de grandària petita. En conclusió, per als diferent models estudiats mitjançant simulació, demostrem que la millor correcció del biaix la proporciona el Propensity Score, en particular, emprat de manera binària inclús quan la mostra és petita. Emprant aquest ajustament en les dades clíniques, obtenim que els malalts que fan alo-trasplantament tenen un risc de morir entre [0,611; 2,711] respecte als malalts que fan quimioteràpia, la qual cosa ens indica que no hi ha diferències estadísticament significatives entre ambdós grups de malalts tractats.
- Published
- 2008
34. Mikhail Shirman 1954-1987
- Abstract
Hand lettered poster with image of refusenik Mikhail Shirman and black border in the style of a death notice. Shirman died of leukemia in Israel following a bone marrow transplant from his only sibling who was delayed from leaving the Soviet Union by its restrictive immigration policy.
- Published
- 1987
35. Medical Management of Hematological Malignant Diseases
- Author
-
Kantarjian, Hagop, Freireich, Emil J., Kantarjian, Hagop, and Freireich, Emil J.
- Subjects
- Leukemia--Treatment, Lymphomas--Treatment
- Published
- 1998
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.